Key result
Severe pediatric HCM linked to a ~4-fold higher likelihood of harboring pathogenic MYBPC3 variants.
Why the study?
Genotype-phenotype correlations in pediatric hypertrophic cardiomyopathy are not well established, and determining gene-variant associations with disease severity may impact clinical care.
Does the presence of pathogenic genetic variants correlate with disease severity (LVH) in children with primary hypertrophic cardiomyopathy?
Observational (n=143)
Single-blind (echocardiographic core lab blinded to genotype)
Yes
Does the presence of pathogenic genetic variants correlate with disease severity (LVH) in children with primary hypertrophic cardiomyopathy?
In pediatric HCM, severe hypertrophy is strongly associated with younger age at diagnosis and pathogenic variants in MYBPC3, highlighting the importance of early genetic testing.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Given the early age of onset, clinical screening should not be delayed but initiated at the time risk status is confirmed. Our data support the conclusion that clinical genetic testing of all children with HCM is indicated and should be followed by cascade testing after a familial disease-associated variant is identified.”
“This finding should not be interpreted to mean that MYBPC3 missense variants are uniformly more penetrant or malignant than truncating variants. The observed association may therefore reflect a limited number of unique variants, the influence of recurrent variants, or unmeasured genetic and nongenetic modifiers.”
Supports earlier genetic testing consideration in severe pediatric HCM; leaves open whether MYBPC3 variants alter outcomes or management.
BACKGROUND: Genotype-phenotype correlations in pediatric hypertrophic cardiomyopathy (HCM) are not well established. Determining whether specific genes or variants correlate with disease severity may impact clinical care. OBJECTIVES: This study aims to identify associations between pathogenic genetic variants in pediatric HCM and echocardiographic maximal left ventricular wall thickness. METHODS: Children with primary HCM from pediatric cardiomyopathy centers were recruited for research-based exome sequencing. Associations between genetic findings, imaging, and clinical outcomes were assessed. Genetic variants in established HCM genes were classified according to established guidelines. Left ventricular hypertrophy (LVH) at enrollment was classified as mild (z-score <12), moderate (z-score ≥12), or severe (z-score ≥17) based on LV septal or posterior wall thickness z-scores measured by a core echocardiography laboratory. RESULTS: Severity of LVH was determined in 143 children with adequate echocardiograms. The median age at enrollment was 11.5 years (range: 3.8-14.4 years). Overall, 51% had a pathogenic variant, of which 93% were in sarcomeric genes. Children with severe LVH (n = 40, 28%) were diagnosed at younger ages than those with mild LVH (n = 78, 55%) at a median of 6.4 vs 12.9 years, P = 0.005. Those with severe LVH were more likely to have pathogenic variants; this association was driven by variants in MYBPC3 (OR: 4.1; 95% CI: 1.7-9.9). Missense variants in MYBPC3 predominated over stop, insertion-deletion, or splicing variants in severe cases. CONCLUSIONS: In this population of children with primary HCM, severe LVH was associated with a younger age at enrollment and a higher likelihood of harboring a pathogenic variant in MYBPC3. (Genotype-Phenotype Associations in Pediatric Cardiomyopathy [PCM GENES]; NCT01873963).
No takes yet. Share an insight, caveat, or question.
Pahl et al. (2026) conducted an observational in Pediatric Hypertrophic Cardiomyopathy (n=143). Pathogenic genetic variant in MYBPC3 vs. Absence of pathogenic variant in MYBPC3 was evaluated on Severe left ventricular hypertrophy (z-score ≥17) (OR 4.1, 95% CI 1.7-9.9, p=0.002). Severe left ventricular hypertrophy in pediatric hypertrophic cardiomyopathy was associated with a higher likelihood of harboring a pathogenic variant in MYBPC3.
Synapse has enriched 10 related papers. Consider them for comparative context: